GlobeNewswire·Nov 9, 2026, 7:00 AM ET

Nkarta Announces Initial Clinical Data for NKX019 in Myositis and Systemic Sclerosis at ACR Convergence

NKTX

Nkarta announced positive initial clinical data from the Ntrust program for NKX019, an allogeneic CAR NK cell therapy, presented at ACR Convergence 2026.
In myositis, 83% of patients (5/6) treated with 4 billion cells per dose achieved moderate or major responses on the Total Improvement Score with at least three months of follow-up.
In systemic sclerosis, 86% of patients (6/7) treated with 4 billion cells per dose achieved an rCRISS-25 response or greater, while 71% (5/7) achieved an rCRISS-50 response or greater.
Systemic sclerosis patients showed rapid skin improvements at the 4 billion-cell dose, with a median 15-point reduction in modified Rodnan skin score at Day 90.
No immune effector cell-associated toxicities, including CRS, ICANS, IEC-HS, or GvHD, were observed among 40 patients treated across five indications.
There were no deaths or treatment discontinuations due to adverse events, and no cases of fludarabine-associated leukoencephalopathy were reported.
Deep peripheral CD19+ B-cell depletion was observed, with a pattern consistent with a B-cell immune reset in patients with low baseline naïve B cells.
Nkarta amended protocols to compress dosing to Days 0, 2, and 4 based on T-cell recovery data, with plans to evaluate a 6 billion-cell dose level.
The company anticipates FDA interactions regarding registrational pathways and expects to report additional clinical follow-up and dose selection plans in the first half of 2027.
An investor webcast regarding these translational data was scheduled for November 9, 2026.

Company: Nkarta, Inc.
Keywords: Nasdaq:NKTX, Nkarta, Inc., autoimmune, myositis, scleroderma, rheumatology, cell therapy, dermatology